实用临床医药杂志2013，Vol.17Issue(9)：98-100,3.DOI:10.7619/jcmp.201309035
复方异丙托溴铵溶液联合布地奈德混悬液雾化吸入治疗D组慢性阻塞性肺疾病患者的临床疗效分析
Effect of inhaled compound ipratropium bromide solution combined with budesonide suspension in patients with AECOPD of group D
赵新国 1张洪明 1陈季北1
作者信息
- 1. 江苏省盐城市第三人民医院呼吸科,江苏盐城,224400
- 折叠
摘要
Abstract
Objective To investigate the clinical effect of inhaled compound ipratropium bromide solution combined with budesonide suspension in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) of group D.Methods Sixty patients with AECOPD of group D were randomly divided into treatment group and control group with 30 in each group.The treatment group received inhaled compound ipratropium bromide solution combined with budesonide suspension plus regular anti-infection,anti-wheezing,oxygen and sputum suction while the control group just received the regular treatment.The dyspnea score,6 minute walk distance test(6MWD) and artery blood gas analysis in two groups were observed before and 7 days after the treatment respectively.Results There were no statistical differences in the dyspnea score,6 MWD,pH value,Pa(O2) and Pa(CO2) of the two groups before the treatment(all P ＞0.05).There were statistical differences in the dyspnea score,6MWD,pH value,Pa(O2) and Pa(CO2) of the two groups 7 days after the treatment compared with those before the treatment(all P ＜ 0.05).There were statistical differences in the dyspnea score,6MWD,pH value,Pa(O2) and Pa(CO2) of the treatment group compared with the control group 7 days after the treatment (all P ＜ 0.05).Conclusion The inhaled compound ipratropium bromide solution combined with budesonide suspension is efficient in the treatment of patients with AECOPD of group D.关键词
复方异丙托溴铵溶液/布地奈德混悬液/慢性阻塞性肺疾病急性加重期/雾化吸入Key words
compound ipratropium bromide solution/budesonide suspension/acute exacerbation of chronic obstructive pulmonary disease(AECOPD)/aerosol inhalation分类
医药卫生引用本文复制引用
赵新国,张洪明,陈季北..复方异丙托溴铵溶液联合布地奈德混悬液雾化吸入治疗D组慢性阻塞性肺疾病患者的临床疗效分析[J].实用临床医药杂志,2013,17(9):98-100,3.
